Inclusion Criteria:

- Histologically/cytologically proven prostate adenocarcinoma that is unresponsive or
refractory to hormone therapy

- Patients must have received prior hormonal therapy, defined as castration by
orchiectomy and/or luteinizing hormone releasing hormone (LHRH) agonists

- Patients must have documented progression detected by PSA increase, physical
examination and/or imaging

- Patients must have achieved stable pain control for a minimum of seven consecutive
days prior to study entry.

- Prior radiation therapy (to < 25% of the bone marrow only) is permitted. At least 4
weeks must have elapsed since the completion of radiation therapy and the patient
must have recovered from side effects prior to study entry.

- Prior surgery is allowed. At least 4 weeks must have elapsed since the completion of
surgery

- Life expectancy > 3 months

- ECOG Performance score of < 2.

- Neutrophil count > 1.5 x 109/L (1,500/mm3)

- Haemoglobin > 10 g/dL

- Platelet count > 100 x 109/L (100,000/mm3)

- Total bilirubin < the upper limit of normal (ULN) of the institution

- ALT (SGPT) and AST (SGOT) < 1.5 x the ULN of the institution

- Calculated creatinine clearance, using Cockroft and Gault formula, >60 mL/min

- APTT and PT < 1.5 X ULN

- Patients (or legally acceptable representative) must have voluntarily given written
informed consent to participate in this study.

- Patients must be willing to comply with the scheduled visit, treatment plans,
laboratory tests, and other study procedures

Exclusion Criteria:

- Prior cytotoxic chemotherapy

- Prior isotope therapy (e.g., strontium, samarium)

- Prior radiotherapy to >25% of bone marrow (whole pelvic irradiation is not allowed)

- Prior treatment with biological response modifiers within the previous 4 weeks

- Prior malignancy except the following: adequately treated basal cell or squamous cell
skin cancer, or any other cancer from which the patient has been disease-free for > 5
years

- Known brain or leptomeningeal involvement

- Symptomatic peripheral neuropathy > grade 2 according to the NCI Common Terminology
Criteria for Adverse Events v3 (NCI CTCAE v3)

- Serious intercurrent medical illness that does not permit adequate follow-up and
compliance with the study protocol

- History of immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura or
other platelet disease, or laboratory evidence of anti-heparin antibodies

- Use of drugs that may inhibit the metabolism of docetaxel (cyclosporin, terfenadine,
ketoconazole, erythromycin, troleandomycin) within the previous week or during the
study

- Concurrent treatment with other experimental drugs. Participation in another clinical
trial with any investigational drug within 30 days prior to study screening

- Treatment with any other anti-cancer therapy (except LHRH agonists) including any
prescribed compounds and/or over-the-counter (OTC) products for the treatment of
prostate cancer must be stopped prior to day of enrolment

- Treatment with systemic corticosteroids used for reasons other than specified by the
protocol must be stopped prior to day of enrolment

- Concomitant bisphosphonate therapy is not allowed. Patients already receiving
bisphosphonates must be stopped prior to day of enrolment

- Concomitant use of aspirin (> 150 mg/day), non-steroidal anti-inflammatory drugs
(except specific COX-2 inhibitors), heparin, low molecular weight heparin (LMWH),
warfarin (> 1 mg/day) or anti-platelet drugs (abciximab, clopidogrel, dipyridamole,
ticlopidine and tirofiban). Low-dose aspirin (≤ 150 mg/day) and low-dose warfarin (≤
1 mg/day) are permitted as concomitant medications

- Treatment with heparin or low molecular weight heparin within the previous two weeks
is not permitted

- History of allergy and/or hypersensitivity to heparin or other
anti-coagulants/thrombolytic agents

- History of acute or chronic gastrointestinal bleeding within the last two years,
inflammatory bowel disease or other abnormal bleeding tendency

- Patients at risk of bleeding due to open wounds or planned surgery

- Myocardial infarction, stroke or congestive heart failure within the past three
months

- Uncontrolled or serious infection within the past four weeks